TheAnswerPage

JANUARY 11, 2022

Since 2012, TheAnswerPage.com has addressed the immense need for unbiased evidence-based high quality education focused on the endocannabinoid system and medical marijuana. TheAnswerPage creates tailored medical cannabis educational programs for Departments of Public Health, state medical societies, hospitals, and medical schools.

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

JUNE 15, 2021

However, the scientific data on CBG is nowhere near as developed as what we have on CBD. The first mention of it we found on the web was a 2012 news article from the Los Angeles Times , telling the story of then-five-year-old Jayden David, a boy who was suffering from Dravet syndrome, a rare form of treatment-resistant epilepsy.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JUNE 1, 2021

She enjoyed commercial success in Latin America managing Merck’s Diversified Brands, including Bacillus Calmette–Guérin (BCG) in 2011 and 2012. Drake received her bachelor’s degree from Wichita State University and is a graduate of the Harvard Business School Executive Leadership Program. About Sesen Bio. Sesen Bio, Inc.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. The MDMA Therapy Training Program was created to train the next generation of psychedelic therapists. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. David joined the faculty at UC Davis in 2015, where he established a research program at the interface of chemistry and neuroscience.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

NORML

JANUARY 28, 2019

according to a 2012 study issued by the Foundation for a Healthy Kentucky. It’s understandable lawmakers want reliable data before making a decision. The good news for Kentucky legislators is the data already i s available. We can all agree on objective scientific data. 8 – state Rep.

Data 191

Data Clinical Trials Chronic Pain Medicine 191